Table I.

List of biomarkers that presented ≥2 risk ratios compared with the control populations (high reliable markers).

			Result
Authors	Biomarker	Endpoint	Condition	HR	95% CI	No.	Sample	Periods	(Refs.)
Johansson et al	RARA	RFS	Low RARA	1.0	–	72	Blood	1991–1996	(7)
			High RARA	4.1	1.55–11.0 (P=0.046)
Ellis et al	Aromatase	BCSS	Absent	1.0	–	169	Biopsy	1998–1999	(15)
			Present	3.76	1.4–10.0 (P=0.008)
Pang et al	Osteopontin	DFS	Low	1.0	–	200	Biopsy	2002	(18)
			High	3.094	1.229.7.789 (P=0.016)
		OS	Low	1.0	–
			High	2.558	1.048–6.243 (P=0.039)
Ohno et al	Ki-67	pCR	<10	1.0	–	504	Biopsy	2002–2004	(21)
			≥10	2.718	1.331–5.549 (P=0.0061)
Denkert et al	Ki-67	pCR	0–15%	1.0	–	1,166	Biopsy	2002–2005	(22)
			15.1–35%	3.3 2	–
			>35%	9.2	− (P=0.00005)
DeCensi et al	Ki-67	OS	Pre-tamoxifen <20	1.0	–	86	Biopsy	2004–2007	(24)
			≥20	3.66	0.81–16.47 (P=0.128)
			Post-tamoxifen <20	1.0	–
			≥20	5.50	1.26–23.16 (P=0.006)
Tsang et al	CEACAM6	OS	CEACAM6 (−)	1.0	–	312	Biopsy	2003–2009	(28)
			CEACAM6 (+)	4.107	1.478–11.417 (P=0.007)
Cizkova et al	PIK3CA	DFS	Wild type	1.0	–	80	Biopsy	2007	(31)
			Mutant type	4.26	1.4–13 (P=0.0063)
Zhu et al	TIMP-	DFS	Low	1.0	–	99	Biopsy	2008	(36)
			High	3.085	1.096–8.680 (P=0.033)
		OS	Low	1.0	–
			High	12.907	1.499–111.2 (P =0.020)

RARA, Retinoic acid receptor α; RFS, recurrence-free survival; BCSS, breast cancer-specific survival; pCR, pathological complete response; CEACAM6, Carcinoembryonic antigen-related cell adhesion molecule 6; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase; catalytic subunit α; TIMP-1, Tissue inhibitor of metalloproteinases-1; DFS, disease free survival; OS, overall survival.